Hideko Ohama

47PUBLICATIONS
95CO-AUTHORS
Predictive and prognostic markersHaematologyCancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classifiedInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (47)

|Jul 15, 2026
Development of a Risk-Estimation Model for Identifying Patients at Risk of Early Skeletal Muscle Mass Loss in Chronic Liver Disease.

|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

|May 11, 2026
Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma.

|Apr 21, 2026
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

|Apr 10, 2026
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab.

Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka

|Feb 26, 2026
Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.

Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka

Pageof 8

Frequent Collaborators

38 joint publications

Atsushi Hiraoka

32 joint publications

Yoichi Hiasa

29 joint publications

Takeshi Hatanaka

29 joint publications

Hidenori Toyoda